Corrigendum to “Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer” [Gynecologic Oncology Volume 161, Issue 3, June 2021, Pages 676-680] (Gynecologic Oncology (2021) 161(3) (676–680), (S0090825821002298), (10.1016/j.ygyno.2021.03.009))

Rodney P. Rocconi, Bradley J. Monk, Adam Walter, Thomas J. Herzog, Evanthia Galanis, Luisa Manning, Ernest Bognar, Gladice Wallraven, Laura Stanbery, Phylicia Aaron, Neil Senzer, Robert L. Coleman, John Nemunaitis

Research output: Contribution to journalComment/debatepeer-review

Fingerprint

Dive into the research topics of 'Corrigendum to “Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer” [Gynecologic Oncology Volume 161, Issue 3, June 2021, Pages 676-680] (Gynecologic Oncology (2021) 161(3) (676–680), (S0090825821002298), (10.1016/j.ygyno.2021.03.009))'. Together they form a unique fingerprint.

Medicine & Life Sciences